      



 



 

AGREEMENT FOR SHARE EXCHANGE

 



 

THIS AGREEMENT FOR SHARE EXCHANGE (this "Agreement"), dated as of the 6th day
of August, 2008, is by and among China Bio-Immunity Corporation, a Nevada
corporation ("China Bio-Immunity"), and Lawford Asia Limited, a corporation
incorporated under the laws of the British Virgin Islands ("Lawford"), and the
Shareholders of Lawford listed in Exhibit A who execute this Agreement (the
"Shareholders") (collectively referred to as the "Parties").

 



 

RECITALS

 



 

WHEREAS, China Bio-Immunity and Lawford desire to complete a share exchange
transaction pursuant to which China Bio-Immunity shall acquire all of the
issued and outstanding common stock of Lawford in exchange for the issuance of
13,246,697 shares of restricted common stock of China Bio-Immunity to the
Shareholders; and

 



 

WHEREAS, the Board of Directors of China Bio-Immunity and the Board of
Directors of Lawford have each approved the proposed transaction, contingent
upon satisfaction prior to closing of all of the terms and conditions of this
Agreement; and

 



 

WHEREAS, the Shareholders are the owners of all of the issued and outstanding
common stock of Lawford; and

 



 

WHEREAS, the Parties desire to make certain representations, warranties and
agreements in connection with completion of the proposed share exchange
transaction.

 



 

NOW, THEREFORE, in consideration of the foregoing recitals, which shall be
considered an integral part of this Agreement, and the covenants, conditions,
representations and

 

warranties hereinafter set forth, the Parties hereby agree as follows:

 



 

ARTICLE I

 

THE EXCHANGE

 



 

1.1

 

 _The Exchange_. At the Closing (as hereinafter defined), China Bio-Immunity
shall acquire all of the issued and outstanding common stock of Lawford from
the Shareholders. Consideration to be issued by China Bio-Immunity shall be a
total of 13,246,697 restricted shares of its common stock (the "Exchange
Shares") in exchange for 100% of the issued and outstanding common stock of
Lawford (the "Exchange"). The Exchange shall take place upon the terms and
conditions provided for in this Agreement and in accordance with applicable
law. Immediately following completion of the share exchange transaction
through issuance of the Exchange Shares, China Bio-Immunity shall have a total
of approximately 15,000,000 shares of its common stock issued and outstanding. 

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

1

 



 



 



 

1.2

 

 _Closing and Effective Time_. Subject to the provisions of this Agreement,
the Parties shall hold a closing (the "Closing") on (i) the first business day
on which the last of the conditions set forth in Article V to be fulfilled
prior to the Closing is fulfilled or waived or (ii) such other date as the
Parties hereto may agree (the "Closing Date"), at such time and place as the
Parties hereto may agree. Such date shall be the date of Exchange (the
"Effective Time"). __

 



 

ARTICLE II

 

REPRESENTATIONS AND WARRANTIES

 



 

2.1

 

 _Representations and Warranties of China Bio-Immunity_. China Bio-Immunity
represents and warrants to Lawford as follows:

 



 

(a)

 

 _Organization, Standing and Power_. China Bio-Immunity is a corporation duly
organized, validly existing and in good standing under the laws of the State
of Nevada, has all requisite power and authority to own, lease and operate its
properties and to carry on its business as now being conducted, and is duly
qualified and in good standing to do business in each jurisdiction in which
the nature of its business or the ownership or leasing of its properties makes
such qualification necessary.

 



 

(b)

 

 _Capital Structure_. As of the date of execution of this Agreement, the
authorized capital stock of China Bio-Immunity consists of 50,000,000 shares
of $0.001 par value common stock of which approximately 1,753,303 shares are
issued and outstanding. The Exchange Shares to be issued pursuant to this
Agreement shall be, when issued pursuant to the terms of the resolution of the
Board of Directors of China Bio-Immunity approving such issuance, validly
issued, fully paid and nonassessable and not subject to preemptive rights.
Except as otherwise specified herein, as of the date of execution of this
Agreement, there are no other options, warrants, calls, agreements or other
rights to purchase or otherwise acquire from China Bio-Immunity at any time,
or upon the happening of any stated event, any shares of the capital stock of
China Bio-Immunity whether or not presently issued or outstanding.

 



 

(c)

 

 _Certificate of Incorporation, Bylaws, and Minute Books_. The copies of the
Articles of Incorporation and of the Bylaws of China Bio-Immunity which have
been delivered to Lawford are true, correct and complete copies thereof. 

 



 

(d)

 

 _Authority_. China Bio-Immunity has all requisite power and authority to
enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby have been duly authorized by the Board of
Directors of China Bio-Immunity. No other corporate or shareholder
proceedings on the part of China Bio-Immunity are necessary to authorize the
Exchange, or the other transactions contemplated hereby.

 



 

(e)

 

 _Conflict with Other Agreements; Approvals_. The execution and delivery of
this Agreement does not, and the consummation of the transactions contemplated
hereby will not result in any violation of, or default (with or without notice
or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation or the loss of a material
benefit under, or the creation of a lien, pledge, security interest or

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

2

 



 



 



 



 



 

other encumbrance on assets (any such conflict, violation, default, right of
termination, cancellation or acceleration, loss or creation, a "violation")
pursuant to any provision of the Articles of Incorporation or Bylaws or any
organizational document of China Bio-Immunity or, result in any violation of
any loan or credit agreement, note, mortgage, indenture, lease, benefit plan
or other agreement, obligation, instrument, permit, concession, franchise,
license, judgment, order, decree, statute, law, ordinance, rule or regulation
applicable to China Bio-Immunity which violation would have a material adverse
effect on China Bio-Immunity taken as a whole. No consent, approval, order or
authorization of, or registration, declaration or filing with, any court,
administrative agency or commission or other governmental authority or
instrumentality, domestic or foreign (a "Governmental Entity") is required by
or with respect to China Bio-Immunity in connection with the execution and
delivery of this Agreement by China Bio-Immunity or the consummation by China
Bio-Immunity of the transactions contemplated hereby. 

 

(f)

 

 _Books and Records_. China Bio-Immunity has made and will make available for
inspection by Lawford upon reasonable request all the books of China Bio-
Immunity relating to the business of China Bio-Immunity. Such books of China
Bio-Immunity have been maintained in the ordinary course of business. All
documents furnished or caused to be furnished to Lawford by China Bio-Immunity
are true and correct copies, and there are no amendments or modifications
thereto except as set forth in such documents.

 

(g)

 

 _Compliance with Laws_. China Bio-Immunity is and has been in compliance in
all material respects with all laws, regulations, rules, orders, judgments,
decrees and other requirements and policies imposed by any Governmental Entity
applicable to it, its properties or the operation of its businesses. 

 

(h)

 

 _SEC Filings._

 

China Bio-Immunity is a reporting Company with the Securities and Exchange
Commission and is current in all of its required reporting obligations.

 

 (i)

 

 _Liabilities_. China Bio-Immunity has no outstanding liabilities as of the
date of execution of the Agreement.

 

(j)

 

 _Litigation_. There is no suit, action or proceeding pending, or, to the
knowledge of China Bio-Immunity, threatened against or affecting China Bio-
Immunity which is reasonably likely to have a material adverse effect on China
Bio-Immunity, nor is there any judgment, decree, injunction, rule or order of
any Governmental Entity or arbitrator outstanding against China Bio-Immunity
having, or which, insofar as reasonably can be foreseen, in the future could
have, any such effect.

 

(k)

 

 _Tax Returns_. China Bio-Immunity has duly filed any tax reports and returns
required to be filed by it and has fully paid all taxes and other charges
claimed to be due from it by any federal, state or local taxing authorities.
There are not now any pending questions relating to, or claims asserted for,
taxes or assessments asserted upon China Bio-Immunity.

 

(l)

 

 _Indemnification_. China Bio-Immunity agrees to defend, indemnify and hold
harmless Lawford and all of Lawfords officers, directors, stockholders,
employees and agents against any and all expenses, costs, and damages (other
than costs and expenses

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

3

 



 



 



 



 



 

directly incurred by Lawford and the officers, directors, stockholders,
employees and agents of Lawford in the process of their due diligence
investigation), including, but not limited to all expenses of defense and
investigation relating thereto, of any and every nature and description,
however incurred, arising out of any wrongful or negligent act or omission by
China Bio-Immunity or any designee of China Bio-Immunity related to the Letter
of Intent, this Agreement, the transactions described herein, and any
agreements or proceedings related to any of them.

 

(m)

 

 _Warrants_. Pursuant to the terms of a Stock Purchase Agreement, dated
December 14, 2007, China Bio-Immunity Corporation is required to issue J.
Michael Coombs, warrants to purchase a total of 100,000 shares of China Bio-
Immunitys common stock. The warrants are exercisable at a price of $0.50 per
share for a term of five years and carry "piggyback" registration rights.

 

(n)

 

 _Advisory Agreement_. Pursuant to the terms of an Advisory Agreement dated
May 13, 2008, by and between China Bio-Immunity Corporation and Mid-
Continental Securities Corp., the Company is required to issue Mid Continental
Securities Corp. and/or its agents or assigns a total of 600,000 shares of
common stock of China Bio-Immunity.

 

2.2

 

 _Representations and Warranties of Lawford_. Lawford represents and warrants
to China Bio-Immunity as follows: __

 



 

(a)

 

 _Organization, Standing and Power_. Lawford is a corporation duly organized,
validly existing and in good standing under the laws of the British Virgin
Islands, has all requisite power and authority to own, lease and operate its
properties and to carry on its business as now being conducted, and is duly
qualified and in good standing to do business in each jurisdiction in which
the nature of its business or the ownership or leasing of its properties makes
such qualification necessary.

 



 

(b)

 

 _Subsidiary_. Lawford is the registered and beneficial owner of 100% of the
issued and outstanding capital stock of JINA Immunity Investment Company
Limited ("JINA"), a corporation incorporated under the laws of Hong Kong, and
JINA is the beneficial owner of 100% of the issued and outstanding capital of
Dalian Jingang-Andi Bio-Products, Co., Ltd., ("JGAD") a corporation
incorporated under the laws of the Peoples Republic of China. 

 



 

(c)

 

 _Capital Structure_. The authorized capital stock of Lawford consists of
50,000 shares of common stock, par value US$1.00 per share. As of the date of
execution of this Agreement, Lawford has a total of 7,500 shares of common
stock issued and outstanding. All outstanding shares of Lawford stock are
validly issued, fully paid and nonassessable and not subject to preemptive
rights or other restrictions on transfer. All of the issued and outstanding
shares of Lawford were issued in compliance with all applicable securities
laws. Except as otherwise specified herein, there are no options, warrants,
calls, agreements or other rights to purchase or otherwise acquire from
Lawford at any time, or upon the happening of any stated event, any shares of
the capital stock of Lawford.

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

4

 



 



 



 



 



 



 

(d)

 

 _Certificate of Incorporation, Bylaws and Minute Books_. The copies of the
Articles of Incorporation and of the other corporate documents of Lawford
which have been delivered to China Bio-Immunity are true, correct and complete
copies thereof. The minute books of Lawford which have been made available
for inspection contain accurate minutes of all meetings and accurate consents
in lieu of meetings of the Board of Directors (and any committee thereof) and
of the shareholders of Lawford since the date of incorporation and accurately
reflect all transactions referred to in such minutes and consents in lieu of
meetings.

 



 

(e)

 

 _Authority_. Lawford has all requisite power to enter into this Agreement
and, subject to approval of the proposed transaction by the holders of 100% of
its issued and outstanding shares which are entitled to vote to approve the
proposed transaction, has the requisite power and authority to consummate the
transactions contemplated hereby. Except as specified herein, no other
corporate or shareholder proceedings on the part of Lawford are necessary to
authorize the Exchange and the other transactions contemplated hereby. 

 



 

(f)

 

 _Conflict with Agreements; Approvals_. The execution and delivery of this
Agreement does not, and the consummation of the transactions contemplated
hereby will not, conflict with, or result in any violation of any provision of
the Certificate of Incorporation or Bylaws of Lawford or of any loan or credit
agreement, note, mortgage, indenture, lease, benefit plan or other agreement,
obligation, instrument, permit, concession, franchise, license, judgment,
order, decree, statute, law, ordinance, rule or regulation applicable to
Lawford or its properties or assets. No consent, approval, order or
authorization of, or registration, declaration or filing with, any
Governmental Entity is required by or with respect to Lawford in connection
with the execution and delivery of this Agreement by Lawford, or the
consummation by Lawford of the transactions contemplated hereby.

 



 

(g)

 

 _Financial Statements_. On or before the date of Closing hereunder, Lawford
shall have delivered to China Bio-Immunity audited financial statements for
its operating subsidiary, JGAD, for the fiscal years ended December 31, 2006
and December 31, 2007, audited in accordance with US GAAP, and unaudited
financial statements for any subsequent interim period. 

 



 

(h)

 

 _Books and Records_. Lawford has made and will make available for inspection
by China Bio-Immunity upon reasonable request all the books of account,
relating to the business of Lawford. Such books of account of Lawford have
been maintained in the ordinary course of business. All documents furnished
or caused to be furnished to China Bio-Immunity by Lawford are true and
correct copies, and there are no amendments or modifications thereto except as
set forth in such documents.

 



 

(i)

 

 _Compliance with Laws_. Lawford is and has been in compliance in all
material respects with all laws, regulations, rules, orders, judgments,
decrees and other requirements and policies imposed by any Governmental Entity
applicable to it, its properties or the operation of its businesses. 

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

5

 



 



 



 



 



 



 

(j)

 

 _Liabilities and Obligations_. Lawford has no material liabilities or
obligations (absolute, accrued, contingent or otherwise) except (i)
liabilities that are reflected and reserved against on the Lawfords financial
statements which are to be delivered to China Bio-Immunity pursuant to
subparagraph (f) above, have not been paid or discharged since the date
thereof and (ii) liabilities incurred since the date of such financial
statements in the ordinary course of business consistent with past practice
and in accordance with this Agreement.

 



 

(k)

 

 _Litigation_. There is no suit, action or proceeding pending, or, to the
knowledge of Lawford threatened against or affecting Lawford, which is
reasonably likely to have a material adverse effect on Lawford, nor is there
any judgment, decree, injunction, rule or order of any Governmental Entity or
arbitrator outstanding against Lawford having, or which, insofar as reasonably
can be foreseen, in the future could have, any such effect.

 



 

(l)

 

 _Taxes_. Lawford has filed or will file within the time prescribed by law
(including extension of time approved by the appropriate taxing authority) all
tax returns and reports required to be filed with all other jurisdictions
where such filing is required by law; and Lawford has paid, or made adequate
provision for the payment of all taxes, interest, penalties, assessments or
deficiencies due and payable on, and with respect to such periods. Lawford
knows of (i) no other tax returns or reports which are required to be filed
which have not been so filed and (ii) no unpaid assessment for additional
taxes for any fiscal period or any basis therefore. 

 



 

(m)

 

 _Licenses, Permits; Intellectual Property_. Lawford owns or possesses in the
operation of its business all material authorizations which are necessary for
it to conduct its business as now conducted. Neither the execution nor
delivery of this Agreement nor the consummation of the transactions
contemplated hereby will require any notice or consent under or have any
material adverse effect upon any such authorizations.

 



 

(n)

 

 _Indemnification_. Lawford agrees to defend, indemnify and hold harmless
China Bio-Immunity and all of China Bio-Immunitys officers, directors,
stockholders, employees and agents against any and all expenses, costs, and
damages (other than costs and expenses directly incurred by China Bio-Immunity
and the officers, directors, stockholders, employees and agents of China Bio-
Immunity in the process of their due diligence investigation), including, but
not limited to all expenses of defense and investigation relating thereto, of
any and every nature and description, however incurred, arising out of any
wrongful or negligent act or omission by Lawford or any designee of Lawford
related to the Letter of Intent, this Agreement, the transactions described
herein, and any agreements or proceedings related to any of them.

 



 

(o)

 

 _Law of Peoples Republic of China_. Lawfords Corporate Structure,
including, but not limited to, its ownership of JGAD, is not in violation of
any laws, rules, or regulations of the Peoples Republic of China.

 



 

2.3

 

 _Representations and Warranties of the Shareholders_. By execution of this
Agreement, each of the Shareholders represents and warrants to China Bio-
Immunity as follows:

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

6

 



 



 



 



 



 



 

(a)

 

 _Shares Free and Clear_. The shares of Lawford which he or she owns are
free and clear of any liens, claims, options, charges or encumbrances of any
nature.

 



 

(b)

 

 _Unqualified Right to Transfer Shares_. He or she has the unqualified right
to sell, assign, and deliver the portion of the shares of Lawford specified on
Exhibit A and, upon consummation of the transactions contemplated by this
Agreement, China Bio-Immunity will acquire good and valid title to such
shares, free and clear of all liens, claims, options, charges, and
encumbrances of whatsoever nature. 

 



 

(c)

 

 _Agreement and Transaction Duly Authorized_. He or she is authorized to
execute and deliver this Agreement and to consummate the share exchange
transaction described herein. Neither the execution and delivery of this
Agreement nor the consummation of the transactions contemplated hereby will
constitute a violation or default under any term or provision of any contract,
commitment, indenture, other agreement or restriction of any kind or character
to which such Shareholder is a party or by which such Shareholder is bound.

 



 

ARTICLE III

 

COVENANTS RELATING TO CONDUCT OF BUSINESS

 



 

3.1

 

 _Covenants of Lawford and China Bio-Immunity_. During the period from the
date of this Agreement and continuing until the Effective Time, Lawford and
China Bio-Immunity each agree as to themselves (except as expressly
contemplated or permitted by this Agreement, or to the extent that the other
party shall otherwise consent in writing):

 



 

(a)

 

 _Ordinary Course_. Each party shall carry on its respective businesses in
the usual, regular and ordinary course in substantially the same manner as
heretofore conducted.

 



 

(b)

 

 _Dividends; Changes in Stock_. No party shall (i) declare or pay any
dividends on or make other distributions in respect of any of its capital
stock, or (ii) repurchase or otherwise acquire, or permit any subsidiary to
purchase or otherwise acquire, any shares of its capital stock.

 



 

(c)

 

 _Issuance of Securities_. No party shall issue, deliver or sell, or
authorize or propose the issuance, delivery or sale of, any shares of its
capital stock of any class, any voting debt or any securities convertible
into, or any rights, warrants or options to acquire, any such shares, voting
debt or convertible securities.

 



 

(d)

 

 _Governing Documents_. No party shall amend or propose to amend its Articles
of Incorporation or Bylaws.

 



 

(e)

 

 _No Dispositions_. Except for the transfer of assets in the ordinary course
of business consistent with prior practice, no party shall sell, lease,
encumber or otherwise dispose of, or agree to sell, lease, encumber or
otherwise dispose of, any of its assets, which are material, individually or
in the aggregate, to such party.

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

7

 



 



 



 



 



 

(f)

 

 _Indebtedness_. No party shall incur any indebtedness for borrowed money or
guarantee any such indebtedness or issue or sell any debt securities or
warrants or rights to acquire any debt securities of such party or guarantee
any debt securities of others other than in each case in the ordinary course
of business consistent with prior practice.

 



 

3.2

 

 _Other Actions_. No party shall take any action that would or is reasonably
likely to result in any of its representations and warranties set forth in
this Agreement being untrue as of the date made (to the extent so limited), or
in any of the conditions to the Exchange set forth in Article V not being
satisfied. 
 

 

ARTICLE IV

 

ADDITIONAL AGREEMENTS AND RELATED TRANSACTIONS

 



 

4.1

 

 _Restricted China Bio-Immunity Shares_. The Exchange Shares will not be
registered under the Securities Act of 1933 (the "Securities Act"), but will
be issued pursuant to applicable exemptions from such registration
requirements for transactions not involving a public offering and/or for
transactions which constitute "offshore transactions" as defined in Regulation
S under the Securities Act. Accordingly, the Exchange Shares will constitute
"restricted securities" for purposes of the Securities Act and the holders of
Exchange Shares will not be able to transfer such shares except upon
compliance with the registration requirements of the Securities Act or in
reliance upon an available exemption therefrom. The certificates evidencing
the Exchange Shares shall contain a legend to the foregoing effect and the
holders of such shares shall deliver at Closing an Investment Letter
acknowledging the fact that the Exchange Shares are restricted securities and
agreeing to the foregoing transfer restrictions.

 



 

4.2

 

 _Access to Information_. Upon reasonable notice, China Bio-Immunity and
Lawford shall each afford to the officers, employees, accountants, counsel and
other representatives of the other company, access to all their respective
properties, books, contracts, commitments and records and, during such period,
each of China Bio-Immunity and Lawford shall furnish promptly to the other (a)
a copy of each report, schedule, registration statement and other document
filed or received by it during such period pursuant to the requirements of
Federal or state securities laws and (b) all other information concerning its
business, properties and personnel as such other party may reasonably request.
Unless otherwise required by law, the Parties will hold any such information
which is nonpublic in confidence until such time as such information otherwise
becomes publicly available through no wrongful act of either party, and in the
event of termination of this Agreement for any reason each party shall
promptly return all nonpublic documents obtained from any other party, and any
copies made of such documents, to such other party.

 



 

4.3

 

 _Legal Conditions to Exchange_. Each of China Bio-Immunity and Lawford shall
take all reasonable actions necessary to comply promptly with all legal
requirements which may be imposed on itself with respect to the Exchange and
will promptly cooperate with and furnish information to each other in
connection with any such requirements imposed upon any of them or upon any of
their related entities or subsidiaries in connection with the Exchange. Each
party shall take all reasonable actions necessary to obtain (and will
cooperate with each other in

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

8

 



 



 



 



 

obtaining) any consent, authorization, order or approval of, or any exemption
by, any Governmental Entity or other public or private third party, required
to be obtained or made by China Bio-Immunity or Lawford or any of their
related entities or subsidiaries in connection with the Exchange or the taking
of any action contemplated thereby or by this Agreement.

 



 

 _4.4_

 

 _Change in Officers and Directors_.

 

In conjunction with Closing under this Agreement, Chipin Tuan will resign as a
director and chief financial officer. However, prior to his resignation, the
Board of Directors of the Company will appoint Quanfeng Wang to serve as
directors of the Company, Aiting Hou to serve as the Chief financial Officer
of the Company, and Lixin Zhou to serve as the Chief Scientist of the Company,
which appointments will become effective as of the Closing under this
Agreement.

 



 

 _4.5_

 

 _Reserved_.

 



 

ARTICLE V

 

CONDITIONS PRECEDENT

 



 

5.1

 

 _Conditions to Each Party\'s Obligation To Effect the Exchange_. The
respective obligations of each party to effect the Exchange shall be
conditional upon the filing, occurring or obtainment of all authorizations,
consents, orders or approvals of, or declarations or filings with, or
expirations of waiting periods imposed by any governmental entity or by any
applicable law, rule, or regulation governing the transactions contemplated
hereby.

 



 

5.2

 

 _Conditions to Obligations of China Bio-Immunity_. The obligation of China
Bio-Immunity to effect the Exchange is subject to the satisfaction of the
following conditions on or before the Closing Date unless waived by China Bio-
Immunity:

 



 

(a)

 

 _Representations and Warranties_. The representations and warranties of
Lawford and of the Shareholders set forth in this Agreement shall be true and
correct in all material respects as of the date of this Agreement and (except
to the extent such representations and warranties speak as of an earlier date)
as of the Closing Date as though made on and as of the Closing Date, except as
otherwise contemplated by this Agreement, and China Bio-Immunity shall have
received a certificate signed on behalf of Lawford by the President of Lawford
and a certificate signed by each of the Shareholders to such effect.

 



 

(b)

 

 _Performance of Obligations of Lawford_. Lawford shall have performed in all
material respects all obligations required to be performed by it under this
Agreement at or prior to the Closing Date, and China Bio-Immunity shall have
received a certificate signed on behalf of Lawford by the President to such
effect.

 



 

(c)

 

 _Closing Documents_. China Bio-Immunity shall have received such
certificates and other closing documents as counsel for China Bio-Immunity
shall reasonably request.

 



 

(d)

 

 _No Dissenting Shares_. Shareholders holding 100% of the issued and
outstanding common stock of number of shares of common stock of Lawford shall
have executed this

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

9

 



 



 



 



 

Agreement and consented to completion of the share exchange transaction
described herein.

 



 

(e)

 

 _Consents_. Lawford shall have obtained the consent or approval of each
person whose consent or approval shall be required in connection with the
transactions contemplated hereby under any loan or credit agreement, note,
mortgage, indenture, lease or other agreement or instrument, except those for
which failure to obtain such consents and approvals would not, in the
reasonable opinion of China Bio-Immunity, individually or in the aggregate,
have a material adverse effect on Lawford and its subsidiaries and related
entities taken as a whole upon the consummation of the transactions
contemplated hereby. Lawford shall also have received the approval of its
shareholders in accordance with applicable law.

 



 

(f)

 

 _Due Diligence Review_. China Bio-Immunity shall have completed to its
reasonable satisfaction a review of the business, operations, finances, assets
and liabilities of Lawford and shall not have determined that any of the
representations or warranties of Lawford contained herein are, as of the date
hereof or the Closing Date, inaccurate in any material respect or that Lawford
is otherwise in violation of any of the provisions of this Agreement.

 



 

(g)

 

 _Pending Litigation_. There shall not be any litigation or other proceeding
pending or threatened to restrain or invalidate the transactions contemplated
by this Agreement, which, in the sole reasonable judgment of China Bio-
Immunity, made in good faith, would make the consummation of the Exchange
imprudent. In addition, there shall not be any other litigation or other
proceeding pending or threatened against Lawford, the consequences of which,
in the judgment of China Bio-Immunity, could be materially adverse to Lawford.

 



 

(h)

 

 _GAAP Audited Financial Statements of JGAD._ China Bio-Immunitys
obligations hereunder shall be contingent upon its receipt of audited
financial statements for JGAD, for the years ended December 31, 2006 and
December 31, 2007, audited in accordance with US GAAP, and unaudited financial
statements for any subsequent interim period, which has been completed more
than 45 days prior to the Closing Date.

 



 

(i)

 

 _Reserved_.

 



 

5.3

 

 _Conditions to Obligations of Lawford_. The obligation of Lawford to effect
the Exchange is subject to the satisfaction of the following conditions unless
waived by Lawford.

 



 

(a)

 

 _Representations and Warranties_. The representations and warranties of
China Bio-Immunity set forth in this Agreement shall be true and correct in
all material respects as of the date of this Agreement and (except to the
extent such representations speak as of an earlier date) as of the Closing
Date as though made on and as of the Closing Date, except as otherwise
contemplated by this Agreement, Lawford shall have received a certificate
signed on behalf of China Bio-Immunity by the President to such effect.

 



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

10

 



 



 



 



 

(b)

 

 _Performance of Obligations of China Bio-Immunity_. China Bio-Immunity shall
have performed in all material respects all obligations required to be
performed by it under this Agreement at or prior to the Closing Date, and
Lawford shall have received a certificate signed on behalf of China Bio-
Immunity by the President to such effect.

 



 

(c)

 

 _Closing Documents_. Lawford shall have received such certificates and other
closing documents as counsel for Lawford shall reasonably request.

 



 

(d)

 

 _Consents_. China Bio-Immunity shall have obtained the consent or approval
of each person whose consent or approval shall be required in connection with
the transactions contemplated hereby.

 



 

(e)

 

 _Due Diligence Review_. Lawford shall have completed to its reasonable
satisfaction a review of the business, operations, finances, assets and
liabilities of China Bio-Immunity and shall not have determined that any of
the representations or warranties of China Bio-Immunity contained herein are,
as of the date hereof or the Closing Date, inaccurate in any material respect
or that China Bio-Immunity is otherwise in violation of any of the provisions
of this Agreement.

 



 

(f)

 

 _Pending Litigation_. There shall not be any litigation or other proceeding
pending or threatened to restrain or invalidate the transactions contemplated
by this Agreement, which, in the sole reasonable judgment of Lawford, made in
good faith, would make the consummation of the Exchange imprudent. In
addition, there shall not be any other litigation or other proceeding pending
or threatened against China Bio-Immunity the consequences of which, in the
judgment of Lawford, could be materially adverse to China Bio-Immunity.

 



 

(g)

 

 _Liabilities_. At or prior to the Effective Date, China Bio-Immunity shall
transfer any and all liabilities on the books out of China Bio-Immunity and
shall provide confirmation in writing that as of the date of Closing it has no
assets and no liabilities.

 



 

5.4

 

 _Reserved_.

 



 

ARTICLE VI

 

TERMINATION AND AMENDMENT

 



 

6.1

 

 _Termination_. This Agreement may be terminated at any time prior to the
Effective Time:

 



 

(a)

 

by mutual written consent of China Bio-Immunity and Lawford;

 



 

(b)

 

by either China Bio-Immunity or Lawford if there has been a material
breach of any representation, warranty, covenant or agreement on the part of
the other set forth in this Agreement which breach has not been cured within
five (5) business days following receipt by the breaching party of notice of
such breach, or if any permanent injunction or other order of a court or other
competent authority

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

11

 



 



 



 



 

preventing the consummation of the Exchange shall have become final and non-
appealable; or

 



 

(c)

 

by China Bio-Immunity if Lawford has not supplied China Bio-Immunity with
financial statements pursuant to Section 5.2(h) hereof on or before September
1, 2008.

 



 

 _6.2_

 

 _Effect of Termination_. In the event of termination of this Agreement by
either Lawford or China Bio-Immunity as provided in Section 6.1, this
Agreement shall forthwith become void and there shall be no liability or
obligation on the part of any party hereto. In such event, all costs and
expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the party incurring such expenses.

 



 

 _6.3_

 

 _Amendment_. This Agreement may be amended by mutual agreement of China Bio-
Immunity, Lawford and the Shareholders, provided that in the case of China
Bio-Immunity and Lawford, any such amendment must be authorized by their
respective Board of Directors, and to the extent required by law, approved by
their respective shareholders. Any such amendment must be by an instrument
in writing signed on behalf of each of the Parties hereto.

 



 

 _6.4_

 

 _Extension; Waiver_. At any time prior to the Effective Time, the Parties
hereto, by action taken or authorized by their respective Board of Directors,
may, to the extent legally allowed, (a) extend the time for the performance of
any of the obligations or other acts of the other Parties hereto, (b) waive
any inaccuracies in the representations and warranties contained herein or in
any document delivered pursuant hereto and (c) waive compliance with any of
the agreements or conditions contained herein. Any agreement on the part of a
party hereto to any such extension or waiver shall be valid only if set forth
in a written instrument signed on behalf of such party.

 



 

ARTICLE VII

 

GENERAL PROVISIONS

 



 

 _7.1_

 

 _Survival of Representations, Warranties and Agreements_. All of the
representations, warranties and agreements in this Agreement or in any
instrument delivered pursuant to this Agreement shall survive the Effective
Time for a period of three years from the date of this Agreement.

 



 

 _7.2_

 

 _Notices_. All notices and other communications hereunder shall be in
writing and shall be deemed given if delivered personally, telecopied (which
is confirmed) or mailed by registered or certified mail (return receipt
requested) to the Parties at the following addresses (or at such other address
for a party as shall be specified by like notice):

 



 

(a)

 

If to:

 

China Bio-Immunity Corporation.

 

10-44 Chester Le Blvd,

 

Toronto, ON M1W2M8

 

Canada 
  

 

(b)

 

If to:

 

Lawford Asia Limited

 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

12

 



 



 



 



 

c/o No. 36 ShengMing 2nd Road

 

DD port, Dalian

 

Peoples Republic of China, 116620

 



 



 

(c)

 

If to the Shareholders, at their respective addresses specified on Exhibit C.

 



 

 _7.3_

 

 _Interpretation_. When a reference is made in this Agreement to Sections,
such reference shall be to a Section of this Agreement unless otherwise
indicated. The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. Whenever the words "include", "includes" or "including" are
used in this Agreement, they shall be deemed to be followed by the words
"without limitation". The phrase "made available" in this Agreement shall
mean that the information referred to has been made available if requested by
the party to whom such information is to be made available.

 



 

 _7.4_

 

 _Counterparts_. This Agreement may be executed in two or more counterparts,
all of which shall be considered one and the same agreement and shall become
effective when two or more counterparts have been signed by each of the
Parties and delivered to the other Parties, it being understood that all
Parties need not sign the same counterpart.

 



 

 _7.5_

 

 _Entire Agreement; No Third Party Beneficiaries; Rights of Ownership_. This
Agreement (including the documents and the instruments referred to herein)
constitutes the entire agreement and supersedes all prior agreements and
understandings, both written and oral, among the Parties with respect to the
subject matter hereof, and is not intended to confer upon any person other
than the Parties hereto any rights or remedies hereunder. 

 



 

 _7.6_

 

 _Governing Law_. This Agreement shall be construed as having been entered
into in the State of Nevada and shall be governed and construed in accordance
with the laws of the State of Nevada without regard to principles of conflicts
of law. Each party hereby irrevocably submits to the jurisdiction of any
Court of Nevada or any federal court in the State of Nevada in respect of any
suit, action or proceeding arising out of or relating to this Agreement, and
irrevocably accept for themselves and in respect of their property, generally
and unconditionally, the jurisdiction of the aforesaid courts.

 



 

 _7.7_

 

 _No Remedy in Certain Circumstances_. Each party agrees that, should any
court or other competent authority hold any provision of this Agreement or
part hereof or thereof to be null, void or unenforceable, or order any party
to take any action inconsistent herewith or not to take any action required
herein, the other party shall not be entitled to specific performance of such
provision or part hereof or thereof or to any other remedy, including but not
limited to money damages, for breach hereof or thereof or of any other
provision of this Agreement or part hereof or thereof as a result of such
holding or order.

 



 

 _7.8_

 

 _Publicity_. Except as otherwise required by law or the rules of the SEC, so
long as this Agreement is in effect, no party shall issue or cause the
publication of any press release or other public announcement with respect to
the transactions contemplated by this Agreement without the written consent of
the other party, which consent shall not be unreasonably withheld.

 



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

13

 



 



 



 



 

 _7.9_

 

 _Assignment_. Neither this Agreement nor any of the rights, interests or
obligations hereunder shall be assigned by any of the Parties hereto (whether
by operation of law or otherwise) without the prior written consent of the
other Parties. Subject to the preceding sentence, this Agreement will be
binding upon, inure to the benefit of and be enforceable by the Parties and
their respective successors and assigns.

 



 



 

 _[signature page follows]_

 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

14

 



 



 



 



 

IN WITNESS WHEREOF, this Agreement for Share Exchange has been signed by the
Parties set forth below as of the date first set forth above.

 



 



 | 
---|--- 
 



|

CHINA BIO-IMMUNITY CORPORATION

  
 



|

("China Bio-Immunity")

  
 



|

 _/s/ Quanfeng Wang____

 

By: Quanfeng Wang

 

Its: Chief Executive Officer

  
 



|


 
 



|

LAWFORD ASIA LIMITED

  
 



|

("Lawford")

  
 



|

 _/s/Quanfeng Wang____

 

By: Quanfeng Wang

 

Its: President

 



  
 



|


 
 



|

SHAREHOLDERS:

  
 



|


 
 



|

 _/s/Quanfeng Wang____

 

QuanFeng Wang

 



 



  
 



|

Wordwise Group Limited

 



 



  
 



 |

 _/s/ Mr. Yu Hong Feng____

 

By: Mr. Yu Hong Feng

  
 



|


 
 



|


 
 



|


 
 



|


 
  



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

15

 



 



 



 



 

EXHIBIT A

 



 | | | 
---|---|---|--- 
 

 _Shareholders of Lawford_

 |

 _No. of shares_

 |



|

 _Percent_

  
 

QuanFeng Wang

 |

1,500

 |



|

20%

  
 

Wordwise Group Limited

 |

6,000

 |



|

80%

  
 

TOTAL

 |

7500

 |



|

100%

  
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
  



 



 



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

16

 



 



 



 



 

EXHIBIT B

 



 



 | | | 
---|---|---|--- 
 

 _Shareholders of China Bio-Immunity After Exchange_

 |

 _No. of shares_

 |



|

 _Percent_

  
 

QuanFeng Wang

 |

2,649,339

 |



|

17.66%

  
 

Wordwise Group Limited

 |

10,597,358

 |



|

70.65%

  
 

Existing Shareholders as specifically identified on China Bio-Immunity
Corporation Shareholder List dated April 18, 2008.

 |



 

1,753,303

 |



|



 

11.69%

  
 



|



|



|


 
 

TOTAL

 |

15,000,000

 |



|

100%

  
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
 



|



|



|


 
  



 



 



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

17

 



 



 



 



 

EXHIBIT C

 

ADDRESSES OF SHAREHOLDERS OF LAWFORD ASIA LTD.

 



 | 
---|--- 
 

 _NAME_

 |

 _ADDRESS_

  
 

 QuanFeng Wang

 |

No.4-1, Building No.14, Song Yu District, Economic and Technology Development
Area, Dalian, Peoples Republic of China

  
 



|


 
 

Wordwise Group Limited

 |

Portcullis TrustNet Chambers, P O Box 3444, Road Town, Tortola, British Virgin
Islands

  
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
 



|


 
  



 



 



 



 



 



 


  

 

 _China Bio-Immunity Corporation  Agreement for Share Exchange_

 

18

 



 



 

     '

